STOCK TITAN

Praxis (PRAX) director Jill DeSimone granted 1,371 RSUs and 648 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Praxis Precision Medicines director Jill DeSimone received new equity awards as part of her compensation. She was granted 1,371 restricted stock units, each representing a right to receive one share of common stock, vesting in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholders meeting.

She also received a stock option for 648 shares of common stock at an exercise price of $240.66 per share, vesting in twelve equal monthly installments beginning July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual meeting. After these grants, she directly holds 2,337 shares of common stock and 648 stock options.

Positive

  • None.

Negative

  • None.
Insider DeSimone Jill
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 648 $0.00 --
Grant/Award Common Stock 1,371 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 648 shares (Direct, null); Common Stock — 2,337 shares (Direct, null)
Footnotes (1)
  1. Ms. DeSimone was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
Restricted stock units granted 1,371 units Contingent right to one common share each; single vesting by 2027
RSU vesting date Earlier of June 10, 2027 or 2027 annual meeting Single annual installment vesting schedule
Stock options granted 648 options Right to buy Praxis common stock
Option exercise price $240.66 per share Stock Option (Right to Buy) granted June 10, 2026
Option vesting schedule 12 equal monthly installments From July 10, 2026 to earlier of June 10, 2027 or 2027 meeting
Option expiration date June 10, 2036 Expiration of stock option right to buy 648 shares
Shares held after transactions 2,337 shares Total Praxis common stock directly owned post-grant
Options held after transactions 648 options Total stock options directly owned post-grant
restricted stock units financial
"Ms. DeSimone was awarded 1,371 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right to receive one share financial
"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... underlying security title: Common Stock"
vest in twelve (12) equal monthly installments financial
"The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month"
annual meeting of stockholders financial
"the date of the Issuer's 2027 annual meeting of stockholders."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DeSimone Jill

(Last)(First)(Middle)
C/O PRAXIS PRECISION MEDICINES, INC.
99 HIGH STREET, 30TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A(1)1,371A$02,337D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$240.6606/10/2026A648 (2)06/10/2036Common Stock648$0648D
Explanation of Responses:
1. Ms. DeSimone was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
Remarks:
/s/ Alex Nemiroff, as Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Praxis (PRAX) director Jill DeSimone report?

Jill DeSimone reported receiving equity compensation awards, not open-market trades. She was granted 1,371 restricted stock units and a stock option for 648 shares of Praxis common stock, both vesting over time based on specified dates tied to the company’s 2027 annual meeting.

How many Praxis (PRAX) restricted stock units were granted to Jill DeSimone?

She was granted 1,371 restricted stock units. Each unit represents a contingent right to receive one share of Praxis common stock, vesting in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service conditions.

What are the terms of Jill DeSimone’s new Praxis (PRAX) stock option?

She received a stock option covering 648 shares of Praxis common stock at an exercise price of $240.66 per share. The option vests in twelve equal monthly installments starting July 10, 2026 and ending on the earlier of June 10, 2027 or the 2027 annual stockholders meeting.

When do Jill DeSimone’s Praxis (PRAX) restricted stock units vest?

The 1,371 restricted stock units vest in a single annual installment on the earlier of June 10, 2027 or the date of Praxis’s 2027 annual meeting of stockholders. Settlement will occur only in shares of Praxis common stock according to the award terms described.

How many Praxis (PRAX) shares does Jill DeSimone hold after these grants?

After the reported transactions, she directly holds 2,337 shares of Praxis common stock. In addition, she holds a stock option for 648 shares, which will become exercisable over time as the monthly vesting schedule progresses through mid-2027 under the award terms.

Are Jill DeSimone’s Praxis (PRAX) Form 4 transactions open-market purchases or sales?

The transactions are equity compensation awards, not market trades. The Form 4 shows grant-type acquisitions of 1,371 restricted stock units and a 648-share stock option, both awarded at a price of $0.00 per share as part of her director compensation package.